Maureen Durkin is professor and chair of population health sciences and Waisman Center investigator at the University of Wisconsin-Madison. She received her undergraduate degree and Ph.D. in anthropology from the University of Wisconsin-Madison and her M.P.H. and Dr.P.H. degrees in epidemiology from Columbia University. Her research focuses on the epidemiology of neurodevelopmental disabilities and childhood injuries, both globally and within the United States. She has collaborated in the development of cross-cultural methods for epidemiologic studies of developmental disabilities and methods for surveillance of childhood injuries and disabilities. She has also directed international studies on the prevalence and causes of neurodevelopmental disabilities in low-income countries. Durkin is currently a principal investigator in the Autism and Developmental Disabilities Monitoring Network and other projects related to public health surveillance, epidemiology and care integration of autism and other developmental disabilities.
Maureen Durkin
Professor of population health sciences
University of Wisconsin-Madison
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.